Latest Market News

AUB Group has reported a robust FY25 with a 17% rise in underlying net profit after tax and increased dividends, setting an optimistic tone for FY26 with growth guidance up to 13.4%.

AUB Group Limited has reported a robust FY25 financial performance, highlighted by a 171% increase in underlying net profit after tax and a 15.2% rise in total dividends. Strategic acquisitions and organic growth across divisions underpin the company’s strong momentum.

Restaurant Brands New Zealand Limited posted record group store sales of NZD 703.2 million for the first half of 2025, driven by strong growth in Hawaii and new store openings in New Zealand. However, profit margins came under pressure from rising costs, leading to a 5.6% drop in net profit after tax.

NZME Limited reported a 3.1% revenue decline for H1 2025 but delivered a 12% rise in operating EBITDA, driven by digital growth and cost efficiencies. The company declared a 3 cent interim dividend amid ongoing economic challenges.

Genesis Energy reported a robust FY25 with a 14% rise in normalised EBITDAF and a 29% jump in net profit, driven by strategic portfolio flexibility amid volatile energy markets. The company accelerated its Gen35 strategy, including key renewable projects and long-term capacity contracts to bolster New Zealand’s energy security.

Metals X Limited reported a robust half-year to June 2025 with profit after tax soaring 256% to $52.9 million, driven by higher tin sales and prices from its Renison joint venture. The company also progressed key projects and deepened strategic investments while reinforcing its ESG and safety frameworks.

Unibail-Rodamco-Westfield has requested suspension of its securities from the ASX, marking the first step toward its official delisting. This move signals a significant shift for investors and the commercial property sector.

Acrow Limited reports a record FY25 with sales up 23%, driven by an 83% jump in its Industrial Access division, now half of group revenue. Despite soft formwork markets, strategic acquisitions and growth initiatives underpin a confident outlook.

Activeport Group has successfully closed a fully underwritten rights issue, raising approximately $2.5 million to support its telecommunications software ambitions. The offer included free attaching options, signaling confidence in future growth.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Platinum Asia Investments has finalized its scheme of arrangement, transferring shares to an ETF structure and delisting from the ASX. Shareholders now hold units in the Platinum Asia Fund Complex ETF as the company undergoes a significant restructure.